However, as increased expression of the cisplatin efflux transporter MRP1 is expected to result in cancer cell resistance, and its correlation with improved clinical response to cisplatin treatment cannot be explained by the current knowledge of MRP1’s pathobiological functions. The gene discussed is ABCC1; the disease is cancer.